Skip to Content
Merck
All Photos(1)

Documents

Safety Information

SHC004V

Sigma-Aldrich

MISSION® pLKO.1-puro TurboGFP™ shRNA Control Transduction Particles

shRNA sequence targeting tGFP

Synonym(s):

MISSION®, MISSION® Control Transduction Particles

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
41106609
NACRES:
NA.51

Quality Level

200

product line

MISSION®

concentration

≥1x106 VP/ml (via p24 assay)

technique(s)

capture ELISA: 106 TU/mL using p24

shipped in

dry ice

storage temp.

−70°C

Looking for similar products? Visit Product Comparison Guide

General description

The MISSION TurboGFP shRNA Control Transduction Particles contain an shRNA sequence targeting TurboGFP. The TurboGFP shRNA Control Particles are useful as a positive knockdown control in experiments using the MISSION TurboGFP positive control vector or in cell lines expressing TurboGFP. TurboGFP is an improved variant of the green fluorescent protein copGFP cloned from copepoda Pontellina plumata.
The TurboGFP shRNA control transduction particles are produced from the sequence-verified lentiviral plasmid, pLKO.1-puro-TurboGFP shRNA (SHC004). Self-inactivating replication incompetent viral particles are produced in packaging cells (HEK293T) by co-transfection with compatible packaging plasmids. In addition, the Control Transduction Particles are pseudotyped with an envelope G glycoprotein from Vesicular Stomatitis Virus (VSV-G), allowing transduction of a wide variety of mammalian cells. 200 μl of 106 TU/ml (via p24 titering assay) lentiviral particles are provided as frozen stock.
When conducting experiments using MISSION® shRNA clones, the proper controls should be a key element of your experimental design to allow for accurate interpretation of knockdown results. The MISSION Control Transduction Particles are a critical positive control to monitor transduction efficiency.
To see more application data, protocols, vector maps visit sigma.com/shrna.

Application

To see more application data, protocols, vector maps visit sigma.com/shrna.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
TurboGFP is a trademark of Evrogen Co.

recommended

Product No.
Description
Pricing

SHC002

MISSION® pLKO.1-puro Non-Mammalian shRNA Control Plasmid DNA, Targets no known mammalian genes

SHC001V

MISSION® pLKO.1-puro Empty Vector Control Transduction Particles, Contains no shRNA insert

SHC003

MISSION® pLKO.1-puro-CMV-TurboGFP™ Positive Control Plasmid DNA, Green fluorescent protein marker to monitor transduction efficiency

SHC002V

MISSION® pLKO.1-puro Non-Mammalian shRNA Control Transduction Particles, Targets no known mammalian genes

SHC003V

MISSION® pLKO.1-puro-CMV-TurboGFP™ Positive Control Transduction Particles, Green fluorescent protein marker to monitor transduction efficiency

SHC004

MISSION® pLKO.1-puro TurboGFP™ shRNA Control Plasmid DNA, shRNA sequence targeting tGFP

SHM01

MISSION® ExpressMag® Super Magnetic Kit, Increases transduction efficiency

SHM02

MISSION® ExpressMag® 96-Well Magnetic Kit, Increases transduction efficiency

SHC016V

MISSION® pLKO.1-puro Non-Target shRNA Control Transduction Particles, Targets no known genes from any species

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

Cartagena Act

Cartagena Act Listed

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mariano J Alvarez et al.
Nature genetics, 50(7), 979-989 (2018-06-20)
We introduce and validate a new precision oncology framework for the systematic prioritization of drugs targeting mechanistic tumor dependencies in individual patients. Compounds are prioritized on the basis of their ability to invert the concerted activity of master regulator proteins

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service